Treatment of climacteric syndrome: a clinical case

Background. The treatment of climacteric syndrome occurring during perimenopause is a pressing issue for the medical community. Currently, treatment of menopausal symptoms is aimed at correcting estrogen deficiency with menopausal hormone therapy. However, there are a number of relative and absolute contraindications for its use. In these situations, it is advisable to consider alternative methods of treating the manifestations of climacteric syndrome.
Objective. To evaluate the possibilities of non-hormonal therapy during the menopausal transition.
Materials and methods. This article describes the clinical case of patient K., who consulted a gynecologist with complaints of menopause, such as hot flashes, night sweats, and irritability, and who had a number of relative contraindications for menopausal hormone therapy. A combination of sulodexide and resveratrol was used as an alternative treatment for menopausal disorders. At the end of treatment, the severity of symptoms and lipid and carbohydrate metabolism indicators were assessed.
Results. After combined therapy, the lipid profile after 3 years showed a 33.42% decrease in low-density lipoprotein cholesterol, very lowdensity lipoprotein cholesterol decreased by 13.75%, triglyceride levels decreased by 12.6%, and total cholesterol decreased by 22.5%. The patient noted that symptoms of night sweats, hot flashes, and irritability became less pronounced, which had a positive effect on her quality of life. The combination of sulodexide and resveratrol has proven effective in relieving menopausal disorders and may be considered for the prevention of cardiometabolic complications in menopause, such as atherosclerosis, hypertension, and thrombotic complications. This aspect requires more in-depth randomized studies.
Conclusion. It is expected that therapy with alternative non-hormonal drugs will not be able to demonstrate an effect completely identical to that of menopausal hormone therapy. However, combination therapy with sulodexide and resveratrol helps prevent the development of cardiometabolic complications: atherosclerosis, arterial hypertension, thrombosis, and thromboembolism. Large-scale randomized studies are needed to evaluate the properties of this combination of drugs.

1. Mittelman-Smith M., Williams H., Krajewski-Hall S. J., McMullen N. T., Rance N. E. Role for kisspeptin/neurokinin B/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature. PNAS. 2012; 109 (48): 19846-19851. https://doi.org/10.1073/pnas.1211517109.

2. ACOG Committee on Clinical Prectice Guidelines – Gynecology. Management of postmenopausal osteoporosis: / ACOG Clinical Practice Guideline No. 2. Obstet. Gynecol. 2022; Vol 139: 698-717.

3. Lapina I. A., Ozolinya L. A., Dobrokhotova Yu. E., Gavrilov M. V., Taranov V. V., Koltinova T. G. Comprehensive assessment of the effect of glucosamine glycans on the hemostasis system in patients with polycystic ovary syndrome. Voprosy ginekologii, akusherstva i perinatologii. 2019; 5 (18): 35-41. (In Russ.)

4. Santoro N., Epperson C. N., Mathews S. B. Menopausal symptoms and their management. Endocrinol. Metab. Clin. North Am. 2015; 3 (44): 497-515.

5. Harikumar K. B., Aggarwal B. B. Resveratrol – a multitargeted agent for age-associated chronic diseases. Cell Cycle. 2008; 8 (7): 1020-1035.